Hudson Science GLP-3 RTA Triple G Pen delivers 16mg of Reta, a triple GLP-1/GIP/Glucagon receptor agonist in a convenient adjustable dose pre filled injection pen. Researched for superior body weight reduction, visceral fat loss, improved insulin sensitivity, and enhanced energy expenditure compared to single and dual incretin agonists. Precise adjustable dosing with no reconstitution required, same day dispatch from within Canada.
FormatAdjustable Dosage Pen
Concentration16mg Adjustable Dosage
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. F40 Biotech’s 16mg adjustable dose pen delivers this triple receptor agonist in a lower concentration adjustable pen presentation compared to the 40mg adjustable dose pen variant, providing researchers with a more accessible entry point into triple incretin agonist pen format research or a practical option for shorter duration protocols and initial dose response characterization at lower concentration points.
The 16mg and 40mg adjustable dose pen presentations serve distinct research purposes within CSD’s GLP-3 RTA pen range. The 16mg format supports initial titration research at the lower end of the triple incretin agonist concentration spectrum. Its particularly relevant for dose escalation protocols that begin at conservative administration levels before progressing to higher concentration points. The adjustable dose mechanism shared across both pen presentations allows researchers to dial precise dose increments without reconstitution preparation, combining the titration flexibility typically associated with lyophilized vial formats with the administration convenience of a ready to use pen system.
CSD’s GLP-3 RTA range now spans the most comprehensive incretin agonist format and concentration selection in our catalogue: lyophilized vials at 20mg, 30mg, 40mg, 50mg, and 60mg across Hudson Science and iLab Pharma, the Hudson Science 10mg 5 pack, and adjustable dose pens at 16mg and 40mg from F40 Biotech. The 16mg pen occupies the lowest concentration position in the adjustable pen format tier. It gives researchers a complete dose escalation pathway from initial low concentration pen evaluation through to extended high concentration vial protocols entirely within the GLP-3 RTA compound family from a single verified Canadian supplier.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s GLP-3 RTA 16mg pen meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds and Semaglutide in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
This was my 3th GLP-3 injection pen from your company . I was very happy with the first 2 that I got. The last injection pen didn’t work at all. The injection were very painful and redness in the injected area last for days. Did not suppress appetite. Disappointed
★★★☆☆NicoleVerified buyer2025-12-16
The pen itself is great, however it doesn’t come with any needles to use.
This Reta injection pen is manufactured by Hudson Science; a verified domestic Canadian supplier producing research grade peptide compounds to CSD's quality standards. All Hudson Science products stocked by CSD are independently HPLC tested by accredited third party laboratories before listing, confirming compound identity as Reta and concentration accuracy at 16mg total content. A certificate of analysis is available on request for this specific lot number.
Reta is a triple receptor agonist simultaneously activating GLP-1, GIP, and glucagon receptors, the most comprehensive incretin based metabolic research compound currently available. It is researched for body weight reduction, visceral and hepatic fat loss, metabolic syndrome management, insulin sensitivity improvement, and cardiovascular risk factor reduction. The additional glucagon receptor agonism produces enhanced energy expenditure and hepatic fat mobilization beyond what dual GLP-1/GIP agonism achieves. Contributing to superior weight reduction outcomes in clinical research versus both Semaglutide and Tirzepatide in comparable research timelines.
The 16mg pen at 10 clicks per 1mg provides up to 16 x 1mg doses or 32 x 0.5mg doses, well suited to initial titration research protocols. A common titration schedule starts at 0.5mg weekly (5 clicks) for 4 weeks consuming 2mg total, escalates to 1mg weekly (10 clicks) for 4 weeks consuming 4mg total, then escalates to 2mg weekly (20 clicks) for 4 weeks consuming 8mg total. The 16mg Hudson Science pen covering the complete 12 week titration phase with 2mg buffer. For researchers beginning at the most conservative 0.5mg weekly dose, the pen provides 32 weekly doses. Sufficient for a complete 32 week low dose research protocol.
Reta is administered subcutaneously once weekly, the same day each week in the abdomen, thigh, or upper arm using a standard pen needle. A gradual dose titration schedule is strongly recommended to minimize gastrointestinal side effects, beginning at 0.5mg weekly (5 clicks) for 4 weeks before escalating in 0.5–1mg increments every 4 weeks based on tolerability. The 6 day half-life supports once weekly administration to maintain stable plasma levels. Attach a fresh pen needle before each injection and dispose safely after use, do not store the pen with a needle attached between injections.
Yes! This Hudson Science batch has been independently HPLC tested by an accredited third party laboratory confirming compound identity as Reta and concentration accuracy at 16mg total content with 0.1mg per click delivery. A certificate of analysis is available.
